To:
ADC Fetal and Neonatal Edition Letters and ADC Education and Practice Letters
Electronic Letters to:
|
|
Electronic letters published:
-
![[Read eLetter]](/icons/misc/sectionDOWN.gif)
Role of high dose methylprednisolone treatment in patients with nephrotic syndrome
- Erol Erduran, Hilal Mocan (16 October 2000)
|
|
|||
|
Erol Erduran, Prof.Dr. in Pediatrics Karadeniz Technical University, Medical School,Trabzon-Turkey; American Hospital, Istanbul-Turkey, Hilal Mocan
Send letter to journal:
erduran{at}ktu.edu.tr Erol Erduran, et al.
|
Dear Editor, I read with great interest a manuscript reported by Hodson et al in the journal (2000;83:45-51. The authors discussed various corticosteroid treatment protocols in patients with nephrotic syndrome (NS). They suggested that children in their first episode of NS should be treated with prednisone for at least three months with an increase in benefit being shown for up to seven months of treatment. We used prednisone (daily 60 mg/m2 for 4 weeks, 45, 30, 20, 5 mg/m2 on alternate days for 4 weeks, respectively) in the treatment of 7 patients with NS (Group I) and compared its effect with the high dose methylprednisolone (HDMP) in a dosage of 30 mg/kg/d for 3 days, 20 mg/kg/d for 4 days, 10 mg/kg/d for a week, perorally, before 9 A.M. in the treatment of 8 patients with NS (Group II).[1] The patients were followed-up for a duration of 38 ± 5.5 months (24-68 months) in Group I and 42 ± 5.5 moths (16-72 months) in Group II. No significant difference was obtained in the duration of remission between two groups (p>0.05), while HDMP induced early remission than prednisone (p<0.05). The mean relapse rates were 0.8/year in both groups. We think that the oral HDMP treatment may be used in the treatment of NS and is more effective in inducing early remission than prednisone. Conclusion, it can be recommended that patients with NS can be treated with the oral HDMP as an alternative treatment to standart oral prednisone treatment. Reference |
|||
